Hologic, Inc. (HOLX)
|Net Income (ttm)||2.04B|
|Day's Range||76.61 - 77.96|
|52-Week Range||60.10 - 85.00|
|Price Target||85.50 (+10.1%)|
|Est. Earnings Date||Nov 3, 2021|
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fus... [Read more...]
Financial PerformanceFinancial Statements
According to 16 analysts, the average rating for Hologic stock is "Buy." The 12-month stock price forecast is 85.50, which is an increase of 10.14% from the latest price.
Hologic (HOLX) closed the most recent trading day at $77.62, moving -0.55% from the previous trading session.
Hologic (HOLX) closed the most recent trading day at $79.95, moving -0.98% from the previous trading session.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.
Overall, nine out of the 15 Exec Comp Aligned with ROIC Stocks outperformed the S&P 500 from July 15, 2021 through August 11, 2021.
Anthem, Nation's Second Largest Health Plan, Now Covers Hologic's Acessa Procedure as a Treatment for Uterine Fibroids
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United Sta...
Covid testing remains 30 percent of Hologic business: CEO
Hologic CEO Steve MacMillan joins Closing Bell to discuss the company's recent earnings and how persistent Covid testing might continue to be as a major part of Hologic's business. MacMillan also explai...
Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.
Hologic (HOLX) delivered earnings and revenue surprises of 19.82% and 12.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Hologic (NASDAQ:HOLX) increased after the company reported Q3 results. Quarterly Results Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2021
The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.
New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recom...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #CDC--New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs)
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) closed at $70.37 in the latest trading session, marking a +1.19% move from the prior day.
The stock price of Hologic, a medical devices company focused on women's health, has seen a 7% rise over the last twenty-one trading days, while it is up just 12% over the last year. Hologic has benefit...
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
Hologic Inc (NASDAQ: HOLX) has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe. The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen'...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test